Homepage
Author:
Oncolytics Biotech, Inc.
Posted Date:
April 6, 2026
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech, Inc.
April 6, 2026
Oncolytics Biotech® Completes Domicile Change to the United States
Oncolytics Biotech, Inc.
April 1, 2026
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Oncolytics Biotech, Inc.
March 19, 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Oncolytics Biotech, Inc.
March 2, 2026
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
Oncolytics Biotech, Inc.
February 24, 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Oncolytics Biotech, Inc.
February 11, 2026
